Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04267120 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT04267120 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 11 participants.
The verdict
NCT04267120, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal carcinoma who have not received any chemotherapy for advanced disease.
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
- PROCEDURE Research blood collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04267120
The ClinicalTrials.gov registry entry for NCT04267120 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT04267120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04267120 about?
NCT04267120 is a clinical study titled "Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)". This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal carcinoma who have not received any chemotherapy for advanced disease.
What is the current status of trial NCT04267120?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-07-29. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT04267120?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG), Research blood collection (PROCEDURE).
Who is sponsoring clinical trial NCT04267120?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.